[1] |
XIE Rui, SUN Qiyue, LI Yanying, ZHANG Jingsheng, ZHAO Ronghua, GUO Shanshan, GENG Zihan, BAO Lei, GAO Shuangrong, CUI Xiaolan, XIE Dan, SUN Jing.
Impacts of Shuangshenling Granules on a Cadmium-Induced Chronic Renal Failure Model of Mice
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 856-862.
|
[2] |
CHEN Siying, DING Xueli, LIU Shujia, ZHANG Xiaomeng, ZHANG Bing, LIN Zhijian.
Modeling for Prediction of Cardiotoxicity of Chinese Herbal Medicines
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 869-875.
|
[3] |
QI Yujie, WANG Xin, ZHANG Jiahui, MA Enlong, GENG Xingchao.
Research Progress in Integration Sites for Cellular and Gene Therapy Products
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 721-727.
|
[4] |
LIN Lin, YANG Tingyu, GAO Rong, MA Zengchun, SHEN Xin, GAO Yue.
Effects of Sinomenine in Brassica rapa L. against Hypoxic Pulmonary Vascular Injury
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(6): 608-613.
|
[5] |
SHEN Lu, LIU Cuili, WANG Yi, HAO Mingqiang, WANG Yali, ZHU Huijuan, WU Chen, YANG Yang.
Precision Pharmacovigilance for Cell and Gene Therapy Products
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(6): 633-639.
|
[6] |
WANG Jiaqing, WANG Qi, LIU Tongtong, ZHANG Dongjie, CHEN Qi, MEI Shenghui, NING Xiao.
Determination of Linezolid Concentrations in Plasma with HPLC-MS/MS Method
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(4): 377-380.
|
[7] |
LAN Xiaoqian, GUO Wei.
Trough Steady-State Concentration/Dose Ratio and Contributors to Adverse Drug Reactions of Sulpiride
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(4): 420-423.
|
[8] |
WANG Shuan, HUANG Can, QI Lamei.
Establishment and Evaluation of Apatinib-Induced Hypertension Prediction Model Based on Real-World Data
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(4): 429-435.
|
[9] |
CAO Yin, ZHOU Xuan, DAI Biao, DENG Yiyun, YAN Chunyu, SHAN Feng, XIA Qingrong, LIANG Jun.
A UPLC-MS/MS method for determination of human serum trazodone concentration and its clinical individualized medications
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 991-997.
|
[10] |
LU Zhenkai, YANG Dingquan, XIE Zhennian, WANG Lianxin, LI Yuanyuan, WANG Zhifei, CUI Xin, XIE Yanming.
Interpretation and insights from the “Guidelines for Pharmacovigilance of Topical Traditional Chinese Medicines in Clinical Applications”
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1029-1033.
|
[11] |
LIN Lu, ZHAN Luchuan, LIU Xiaoqi, LIU Ju'e, WANG Laiyou, ZENG Ying, LAI Weihua.
Establish triggers for active monitoring of digoxin adverse events based on the China hospital pharmacovigilance system
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1039-1043.
|
[12] |
WANG Yijin, TANG Jing, YANG Chao, XU Kai, ZHANG Mengdie, GAO Jian, WU Xiaoli, ZHANG Yue, NIU Xiaobing, JIANG Hesong, MAO Fei, ZHOU Shan, JIANG Xi, GUO Zhongying, SUN Su'an, XU Ming, XU Zongyuan, WANG Hengbing, LI Xin, FU Guangbo.
Clinical research of submucosal low-dose gemcitabine injection combined with transurethral resection of bladder tumor in the treatment of medium-high risk non-muscle invasive bladder cancer
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1044-1050.
|
[13] |
LIU Chang, SHI Chang, YIN Jiye.
Nonclinical immunotoxicity evaluation of CAR-T cell products
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1051-1055.
|
[14] |
ZHANG Caixia, ZHOU Yi, TAN Lu, CHEN Wenming, LIU Yang, YOU Yu.
Pharmaceutical care of pulmonary aspergillus infection secondary to sepsis
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1064-1067.
|
[15] |
ZHANG Qian, YUN Yuan, HE Lian.
Pharmaceutical care of hyperprolactinemia in a patient induced by risperidone
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(8): 936-938.
|